DIPLOMA HEALTH OUTCOME RESEARCH
In cooperation with the Sigmund Freud University Vienna
This program consists of three modules, each focusing on the knowledge and skills required for health outcomes research and health policy making which are designed and lectured by Prof. Lieven Annemans, Past President of ISPOR in cooperation with other members of the VSCR faculty.
The program and its 3 modules will provide the latest knowledge about
- The basic principles of Health Economy and health outcome models
- The provision of health outcome data within the framework of evidence based medicine
- The basic processes and varied natures (landscapes) of Health Technology Assessments (HTA)
- The skills and science behind successful submissions of value dossiers for HTA, reimbursement , market access and successful commercialization
FACULTY: The faculty is comprised of experienced lecturers and experts from academia, governmental authorities, health policy institutions.
Program Directors
TARGET GROUP:
The program is created for members/employees of
Pharmaceutical/Biotech/Medical Device/Industry
Medical, Marketing, Regulatory, Market Access, General Management, etc.
Health Insurers
Health Care Providers / Commissioners
HTA & Consultancy Agencies
Educational & Research Institutions
Health Policy Organizations
The interactive atmosphere during the course ensures effective communication with the faculty and fosters professional exchange and networking between the participants.
Each single module can be booked and attended individually. To subscribe to the 3-module diploma is not mandatory.
Elective modules are part of the overall Diploma program. However, can be registered also individually.
HEALTH ECONOMICS FOR NATIONAL, REGIONAL AND LOCAL HEALTHCARE DECISION MAKING
This special course is an elective module of the Diploma program HEALTH OUTCOME RESEARCH-MARKET ACCESS provided by VSCR and the Sigmund Freud University Vienna (SFU).
However, it can be booked also as an independent module on its own as well.
Target group: Market Access specialists and Key Account Managers, Regulatory and Medical Managers, Purchase Managers in hospitals
For more information, please click here.
STD_VSCR special course_April_2023
COURSE LANGUAGE: English
Currently the program and its modules will be entirely rolled out virtually (online).
Each of these modules are now awarded with a university certificate if successfully attended. In case of a successful attendance/ performance of all three modules an academic diploma – HEALTH OUTCOME – RESEARCH DIPOLMA – will be awarded jointly by the SFU and VSCR.
Date: tba
Lecturer: Prof. Lieven Annemans, Ghent University, Belgium
THE CONTEXT: Economic foundations and societal background of healthcare decision making based on HEOR and HTA
THE TOOLS:
Evidence Based Medicine (EBM)
Health Outcome Studies
Health Economic Models
Real World Evidence (RWE)THE PROCESSES:
Nature and Principles of HTA
LEARNING OBJECTIVES
At the end of this 2-days module, participants will
- Understand the present and future challenges for social health care systems
- Comprehend in detail the evolving burden of disease
- Have insights about current strategies to cope with rising costs in health care
- Understand the impact of data and evidence - based decision making for health care budgets
- Learn about options how to best prioritize spending in health care budgets
- Understand how payors will handle tradeoffs in health care spending
- Learn about the validity of various Health Outcomes studies and the appropriate scenarios to apply
- Get insight into the various kinds of study protocols and how to choose and apply
- Understand the opportunities and limits of Health Outcomes studies in view of the clinical and economic context
- Comprehend the need and value of health economic models and how to apply, read and analyze
- Comprehend the value and opportunity of RWE and how to use and synthetize them into the present bundle of available (conventional) data
- Get insight in future aspects of capturing health outcomes data
- Understand why HTA is a useful process and how it is applied in the context of patient access and health care budget considerations
- Learn about the concept, the basic principles and the formal process of a HTA
- Understand the various steps in the HTA process and the dependance on data availability and data integrity
- Learn how to read, analyze and interpret HTA results and findings
- Be happy that they have participated at this module
Date: tba
Lecturer: Prof. Lieven Annemans, Ghent University, Belgium
2days - 4 hours each
LEARNING OBJECTIVES
At the end of this 2-days module, participants will
• Understand how payers assess technologies depending on their own incentives and setting;
• See the opportunities in changing payment systems for hospitals and clinicians;
• Have insights into the weaknesses of the QALY and the opportunities of disease specific outcome measures;
• Understand the need for a tailored yet coherent value story
• See the options about how to deal via agreements with uncertain evidence
• Understand why health economic evaluations need to start early in the development of medicines/health technologies
• Understand the need to align strategies across functional teams for successful market and patient access of new health technologies
• Have insights in how the development program can anticipate on value - based strategies and access
• Be happy that they have participated at this module
Date: 15 September 2022
SPEAKER HIGHLIGHT:
Lieven Annemans, MSc, PhD
Senior Professor of Health Economics, Ghent University,
Faculty of Medicine and Health Sciences, Belgium
Health economic evaluations throughout a medicine’s development process.
From Target Product Profile to successful patient access.
PRACTICAL WORKSHOP- ONLINE
1 day - 4.5 hours
For more information please contact office@vscr.at
Costs:
Single module: 2,500 euros
Discounts upon request
Diploma ( completion of 3 modules): 6,000 euros
FEEDBACK FROM PARTICIPANTS:
„The course gave me valuable insight for my professional work how HTA methodology is utilized by payer organisations.“
Regional market Access Manager, Merck, Sharp & Dohme
„I valued very much the real life examples showing the various aspects of successful market access strategies.“
Market Access Specialist Europe, Novartis
„I learned a lot through the interactions with representatives from payer organisations who also participated in the course module.“
Regional Market Access Lead, sanofi
„The group exercises are thoughtful and well guided. It helps me in my day to day work.“
Market Access Middle East, Eli Lilly
Get inspired by previous participants and lecturers
Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren